Articles in this issue

• 

  MSCs rising

  Wednesday, July 30, 2025
  With MSCs back in the spotlight and a pipeline of mid- and late-stage candidates pushing toward regulatory submission, what looms now is not a question of whether MSCs can deliver, but the challenge ... read more
• 

  CGT innovation under pressure

  Wednesday, July 23, 2025
  In 2025, a new challenge has taken center stage: A tightening macroeconomic environment that threatens to slow the pace of innovation. read more
• 

  Cellular rebirth

  Wednesday, August 06, 2025
  After decades of research that hadn’t translated into efficacy in patients and a proliferation of unsubstantiated stem cell science, MSCs seemed stuck in therapeutic purgatory, unable to rise from the... read more
• 

  Ferring debuts U.S. facility to tackle manufacturing bottlenecks

  Wednesday, August 13, 2025
  Ferring has spared little expense in its efforts to get Adstiladrin to patients, including nearly $500 million in manufacturing investments. read more
• 

  Navigating the realities of CAR-T cell oncology trials

  Wednesday, August 20, 2025
  Given the undeniably novel aspect of this new paradigm, however, conducting CAR-T clinical trials presents a unique set of obstacles for sponsors, sites and regulators to carefully navigate. Moreover,... read more
• 

  Rethinking iPSC development

  Wednesday, September 10, 2025
  A robust CMC strategy cannot be retrofitted; it should guide decisions from the very beginning. For developers aiming to bring iPSC-based therapies to the commercial market, the starting point is not ... read more
• 

  How digital can ease the burden of cell and gene therapy long-term follow-up

  Wednesday, September 17, 2025
  Because CGTs are designed to have lasting and lifelong effects, regulatory bodies often mandate 15-year, long-term follow-up. Fortunately, collaborative groups are creating resources and ... read more
• 

  Navigating cell therapy's maze of risks

  Wednesday, September 03, 2025
  Biopharma companies advancing cell therapies must confront a range of key considerations and risks. A strategic, collaborative approach can accelerate development and ensure patients reliably access ... read more
• 

  Are LNPs the new AAV?

  Wednesday, August 27, 2025
  The emergence of nonviral vectors represents an opportunity to propel in vivo gene therapy further into commercial adoption and expand its impact globally. LNPs are poised to become the first ... read more